DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,254 filers reported holding DANAHER CORPORATION in Q3 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $59,178,053 | -15.5% | 238,525 | -18.2% | 0.70% | +13.7% |
Q2 2023 | $69,994,080 | -11.6% | 291,642 | -7.2% | 0.61% | -20.1% |
Q1 2023 | $79,200,546 | -2.4% | 314,238 | +2.8% | 0.77% | -9.2% |
Q4 2022 | $81,161,720 | -99.9% | 305,786 | +4.3% | 0.85% | +2.5% |
Q3 2022 | $75,717,455,000 | +102580.3% | 293,149 | +0.8% | 0.82% | +13.2% |
Q2 2022 | $73,741,000 | -8.6% | 290,870 | +5.8% | 0.73% | +17.0% |
Q1 2022 | $80,668,000 | -54.4% | 275,009 | -48.9% | 0.62% | -4.9% |
Q4 2021 | $176,928,000 | +129.2% | 537,758 | +112.1% | 0.66% | -18.5% |
Q3 2021 | $77,181,000 | +14.1% | 253,519 | +0.6% | 0.80% | +6.5% |
Q2 2021 | $67,648,000 | +19.8% | 252,078 | +0.5% | 0.76% | +4.4% |
Q1 2021 | $56,445,000 | -4.3% | 250,777 | -5.5% | 0.72% | -9.7% |
Q4 2020 | $58,962,000 | -22.8% | 265,426 | -25.1% | 0.80% | -30.6% |
Q3 2020 | $76,355,000 | +23.7% | 354,593 | +1.6% | 1.15% | +11.7% |
Q2 2020 | $61,729,000 | +33.4% | 349,086 | +4.4% | 1.03% | +8.5% |
Q1 2020 | $46,273,000 | -8.1% | 334,316 | +1.9% | 0.95% | +8.9% |
Q4 2019 | $50,355,000 | +13.4% | 328,090 | +6.8% | 0.87% | +3.7% |
Q3 2019 | $44,389,000 | +1.3% | 307,338 | +0.2% | 0.84% | +4.5% |
Q2 2019 | $43,824,000 | +1.2% | 306,632 | -6.5% | 0.81% | -2.8% |
Q1 2019 | $43,285,000 | +7.1% | 327,869 | -16.4% | 0.83% | +0.5% |
Q4 2018 | $40,431,000 | -23.1% | 392,079 | -18.9% | 0.83% | -15.0% |
Q3 2018 | $52,543,000 | +15.2% | 483,552 | +4.7% | 0.97% | +8.4% |
Q2 2018 | $45,595,000 | +0.8% | 462,050 | -0.0% | 0.90% | -5.9% |
Q1 2018 | $45,255,000 | +11.7% | 462,211 | +5.9% | 0.95% | +17.8% |
Q4 2017 | $40,526,000 | +5.2% | 436,606 | -2.7% | 0.81% | -7.2% |
Q3 2017 | $38,510,000 | -26.8% | 448,936 | -28.0% | 0.87% | -30.4% |
Q2 2017 | $52,627,000 | -11.5% | 623,620 | -10.3% | 1.25% | -14.9% |
Q1 2017 | $59,467,000 | -3.2% | 695,282 | -11.9% | 1.47% | -7.0% |
Q4 2016 | $61,402,000 | -3.4% | 788,825 | -2.7% | 1.58% | -3.5% |
Q3 2016 | $63,567,000 | -21.8% | 810,905 | +0.7% | 1.64% | -24.6% |
Q2 2016 | $81,301,000 | +7.3% | 804,959 | +0.7% | 2.17% | +9.9% |
Q1 2016 | $75,792,000 | +20.0% | 798,986 | +17.5% | 1.98% | +16.2% |
Q4 2015 | $63,178,000 | +16.8% | 680,216 | +7.1% | 1.70% | +5.5% |
Q3 2015 | $54,096,000 | +4.6% | 634,858 | +4.2% | 1.61% | +19.6% |
Q1 2015 | $51,710,000 | +12.7% | 609,075 | +13.8% | 1.35% | +11.8% |
Q4 2014 | $45,874,000 | +5.4% | 535,225 | -6.6% | 1.21% | +7.7% |
Q3 2014 | $43,518,000 | -18.5% | 572,760 | -15.6% | 1.12% | -16.0% |
Q2 2014 | $53,403,000 | +35.5% | 678,304 | +29.1% | 1.34% | +23.8% |
Q1 2014 | $39,415,000 | -0.1% | 525,532 | +2.8% | 1.08% | -7.3% |
Q4 2013 | $39,453,000 | – | 511,052 | – | 1.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |